1. Allopurinol (4-hydroxypyrazolo[3,4-d]pyrimidine) selectively inhibits the apotryptophan pyrrolase activity in homogenates of rat liver in vitro and after intraperitoneal administration. The inhibition is abolished by an excess of haematin. The allopurinol metabolite alloxanthine has no effect on the pyrrolase activity in vitro or after administration. Allopurinol also inhibits the activation of the enzyme in vitro by ascorbate, ethanol plus NAD+, NADH, hypoxanthine or xanthine. It is suggested that these agents cause the conversion ofa latent form of the pyrrolase into the apoenzyme, and that xanthine oxidase is not involved in this process. 2. The raised total pyrrolase activity observed after the administration of cortisol, cyclic AMP, tryptophan, salicylate or ethanol is lowered by allopurinol in vitro to the corresponding holoenzyme values. A similar effect is observed when allopurinol is administered shortly before cortisol or cyclic AMP. Pretreatment of rats with allopurinol completely prevents the enhancement of the pyrrolase activities by tryptophan, salicylate or ethanol. 3. It is suggested that allopurinol inhibits rat liver tryptophan pyrrolase activity in vitro and after administration by preventing the conjugation of the apoenzyme with its haem activator. The possible usefulness of combined allopurinol-tryptophan therapy of affective disorders is discussed.
1. Allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine) selectively inhibits the apotryptophan pyrrolase activity in homogenates of rat liver in vitro and after intraperitoneal administration. The inhibition is abolished by an excess of haematin. The allopurinol metabolite alloxanthine has no effect on the pyrrolase activity in vitro or after administration. Allopurinol also inhibits the activation of the enzyme in vitro by ascorbate, ethanol plus NAD+, NADH, hypoxanthine or xanthine. It is suggested that these agents cause the conversion ofa latent form of the pyrrolase into the apoenzyme, and that xanthine oxidase is not involved in this process. 2. The raised total pyrrolase activity observed after the administration of cortisol, cyclic AMP, tryptophan, salicylate or ethanol is lowered by allopurinol in vitro to the corresponding holoenzyme values. A similar effect is observed when allopurinol is administered shortly before cortisol or cyclic AMP. Pretreatment of rats with allopurinol completely prevents the enhancement of the pyrrolase activities by tryptophan, salicylate or ethanol. 3. It is suggested that allopurinol inhibits rat liver tryptophan pyrrolase activity in vitro and after administration by preventing the conjugation of the apoenzyme with its haem activator. The possible usefulness of combined allopurinol-tryptophan therapy of affective disorders is discussed.
It has been reported that allopurinol (4-hydroxypyrazolo [3,4-d] pyrimidine) inhibits the activity of rat liver tryptophan pyrrolase (L-tryptophan-O2,oxidoreductase, EC 1.13.1.12) in vitro and after administration (Becking & Johnson, 1967) . The administration of the drug or its addition in vitro also inhibits the activity of the cortisol or tryptophan-induced enzyme (Green & Curzon, 1968; Moon, 1971; Chytil, 1968) . The activity measured in all these studies was that of either the holoenzyme or the total enzyme but not the two simultaneously. Chytil (1968) suggested that the inhibition of tryptophan pyrrolase by allopurinol is a consequence of a similar action on xanthine oxidase activity, and that the activation of the former by cyclic AMP and other purine derivatives is secondary to their enhancement of the latter enzyme activity. The present paper provides evidence suggesting that allopurinol inhibits the activity of rat liver tryptophan pyrrolase in vitro and after administration by preventing the conjugation of the apoenzyme with its haem activator, and that xanthine oxidase does not exert a regulatory effect on tryptophan pyrrolase activity.
Materials and Methods Chemicals
Cortisol 21-acetate, cyclic AMP, dimethylformamide, haemin (haematin hydrochloride), NAD+, NADH and L-tryptophan were from Sigma (London) Vol. 133 Chemical Co., Kingston-upon-Thames, Surrey, U.K. Allopurinol and its metabolite alloxanthine (oxypurinol) were a gift from the Wellcome Foundation Ltd., London NW1 2BP, U.K. Ethanol (99.7-100 %) and all other chemicals (from BDH Chemicals Ltd., Poole, Dorset, U.K.) were of AnalaR grade, except for hypoxanthine, xanthine and sodium salicylate, which were of reagent grade.
Animals and injections
Male (180-290g) Wistar rats, maintained on MRC cube diet no. 41B, were killed between 12:00 and 15:00h by stunning and cervical dislocation. All the chemicals were given intraperitoneally 4h before death except alloxanthine, which was given 2h before death. Additional experiments were performed with allopurinol in which groups of rats were killed at between 15min and 6h after the injection. Cortisol acetate was dissolved in dimethylformamide and 0.1 ml (2mg/lOOg body wt.) was injected; the corresponding control rats received an equal quantity of the solvent, which gave results identical with another control group of rats that had received 0.9% (w/v) NaCI. Tryptophan (20mg) was dissolved in the minimum amount of 1 M-NaOH and diluted to 1 ml with 0.9 % NaCl after the pH had been adjusted to 7.3 with 1 M-HCl;eachrat received 1 ml/l00gbody wt. Sodium salicylate (400mg/kg) was dissolved in0.9 % NaCl and ethanol (5 ml/kg) was given as a 25 % (v/v) solution in Table 1 . Effects ofvarious doses ofallopurinol on rat liver tryptophan pyrrolase activity Each rat received a single intraperitoneal injection ofeither allopurinol (1.5-10 mg/kg body wt.) or an equal volume of 0.9 % (w/v) NaCI 2h before being killed. The enzyme activity was determined as described in the Materials and Methods section in either the absence (holoenzyme activity) or the presence (total enzyme activity) of added haematin (2,tM 0.9% NaCl. Cyclic AMP (5mg/1OOg), alloxanthine (10mg/kg) and allopurinol (1.5-10mg/kg) were dissolved in the minimum amount of lM-NaOH and diluted with 0.9 % NaCl after the pH had been adjusted to 7.4-7.9 with 1M-HCI; each rat received 0.2 ml/l00g body wt. The corresponding control rats received an equal volume of 0.9 % NaCl.
Preparation of homogenates
The liver was removed within 30s ofthe death ofthe animal and was homogenized for 1 min at 1l00rev./ min in 7 volumes of a solution containing 140mM-KCI and 2.5 mM-NaOH at 0°C in a glass homogenizer with a loose-fitting Teflon pestle. The homogenates were used within 4-9min of preparation.
Determination oftryptophan pyrrolase activity
The activity of the enzyme was determined in liver homogenates by measuring the formation of kynurenine from L-tryptophan (Feigelson & Greengard, 1961) either in the absence (holoenzyme activity) or in the presence (total enzyme activity) of added haematin. The apoenzyme activity was calculated by difference. Samples (15ml) of the homogenates were added to a solution containing 5ml of0.03 M-L-tryptophan, 15ml of 0.2M-sodium phosphate buffer, pH7.0 and 25 ml ofwater at 0°C. Where necessary, haematin hydrochloride was dissolved in 0.1 M-NaOH and 0.1 ml was included in the overall mixture to give a concentration (2,UM) that was optimum for enzyme activation. Samples (3 ml) of the mixture were incubated with shaking at 37°C in stoppered 25ml conical flasks in an atmosphere of 02 for appropriate timeintervals (5min each) up by using an E of 4540 litre' molhI cm-'. Tryptophan pyrrolase activity was calculated from the increase in the E365 with time during the linear phase. The latter was preceded by a lag-phase that persisted for 30-45 min with the basal enzyme and the enzyme induced by the administration ofeither cortisol or cyclic AMP. The enzyme enhanced by the administration oftryptophan, salicylate or ethanol or by the addition of activators in vitro had the lag-phase either abolished or shortened to 15min. For an extinction range (at 365rnm) of 0.10-0.75 the line representing the linear phase exactly covered three to four points 15min apart. In the experiments in vitro, ascorbic acid, ethanol, NAD+, NADH, hypoxanthine, xanthine, allopurinol and alloxanthine were dissolved in the sodium phosphate buffer with or without a little 1M-NaOH, neutralized to pH7.3 with 1M-HCl and added immediately before incubation.
Results
Effects of administration of allopurinol on rat liver tryptophan pyrrolase activity Allopurinol, in single intraperitoneal doses of 1.5mg/kg body wt. and above, significantly inhibited the total pyrrolase activity (P<0.05 at least) without affecting that of the holoenzyme. The apoenzyme activity (obtained by difference) was inhibited by 61, 74 and 89% with doses of 1.5, 2.5 and 5mg/kg body wt. respectively and by 100% with higher doses ( Table 1) .
The time-course of the effects of the injection of allopurinol (10mg/kg) on the pyrrolase activity is shown in Fig. 1 . The apoenzyme activity was inhibited by 66 % at 15min and by 100 % at 2h. The inhibition then decreased to 76% at 3 h, 62% at 4h and finally disappeared after 5h. The effects of the administration of allopurinol on the enhancement of the pyrrolase activity by various treatments in vivo is shown in Table 2 . The drug had no significant effect on the rise in the holoenzyme activity caused by either cortisol or cyclic AMP whereas that in the total activity was decreased to the corresponding holoenzyme values. Allopurinol completely prevented the increase in both holoenzyme and total pyrrolase activities produced by tryptophan, sali-. cylate or ethanol.
Effects ofallopurinol on rat liver tryptophan pyrrolase activity in vitro
The results (Table 3) show that allopurinol in concentrations of 2.5 uM and above significantly inhibited the total pyrrolase activity in homogenates of rat liver in vitro. The holoenzyme activity was not altered by any of the concentrations of allopurinol tested.
The inhibition of the apoenzyme activity by allopurinol in vitro or at 2h after intraperitoneal administration was abolished by the addition to the incubation mixture of an excess of haematin (Fig. 2) . The inhibition of the cortisol-induced rise in the apoenzyme activity by allopurinol pretreatment of rats was also reversed by haematin. Allopurinol added in vitro decreased the total pyrrolase activity in livers of rats treated with cortisol, cyclic AMP, tryptophan, salicylate or ethanol to the corresponding holoenzyme values (Table 4) without affecting the latter.
The stimulation of both holoenzyme and total pyrrolase activities by ascorbate, ethanol plus NAD+, NADH, hypoxanthine or xanthine in vitro (Table 5) was completely inhibited by the addition of allopurinol (Table 6 ).
The allopurinol metabolite alloxanthine did not alter the pyrrolase activity in vitro or in vivo. At 0.05mM, it slightly (9-11 %) inhibited the basal enzyme activities in vitro. By 2h after the administration of alloxanthine (10mg/kg body wt.) in the rat, the holoenzyme and total pyrrolase activities were (in ,umol of kynurenine formed/h per g wet wt. of liver ±S.E.M. of each group of four rats) 1.86+0.04 and 3.63 ±0.19 compared with the control (0.9% NaCl) values of 1.53±0.16 and 3.20+0.35 respectively.
Discussion
Allopurinol, a xanthine oxidase inhibitor both in vivo (Elion et al., 1963) and in vitro (Watts et al., 1965) , has been shown to inhibit non-competitively the activity of rat liver tryptophan pyrrolase (Becking & Johnson, 1967) . The drug also inhibits the activation of the pyrrolase by cyclic AMP and other purines which must be converted into hypoxanthine before exerting their action in vitro (Chytil, 1968) . This author suggested that the H202 formed by the action of xanthine oxidase on hypoxanthine causes the conversion of a latent form of the pyrrolase into the apoenzyme. The participation ofxanthine oxidase in the inhibitory action of allopurinol on tryptophan pyrrolase activity was further suggested (Chytil, 1973 Table 4 . Effect of allopurinol (0.05mM) on the total activity of rat liver tryptophan pyrrolase induced by cortisol, cyclic AMP, tryptophan, salicylate and ethanol The total pyrrolase activity was determined 4h after the injection ofvarious inducers as described in Table 2 (Table  5) is completely prevented by allopurinol in vitro (Table 6 ). Whereas hypoxanthine and xanthine are substrates for xanthine oxidase, ascorbate is not, and NADH inhibits the enzyme activity (Della Corte & Stirpe, 1970) . Thus NADH, whether produced during the action of xanthine oxidase on hypoxanthine and/ or xanthine or of alcohol dehydrogenase on ethanol plus NAD+ (Badawy & Evans, 1973a) , may be the pyrrolase activating agent. The activation of tryptophan pyrrolase by the agents listed in Table 5 may be caused by the conversion into the active enzyme of a form(s) that, by using ascorbate as activator, has been described as latent (Knox, 1966) and as monomer (Cho-Chung & Pitot, 1967) . The above findings (Tables 5 and 6 ), the direct inhibition of the pyrrolase activity by allopurinol administration and in vitro (Tables 1 and 3 ) and the absence of inhibition by the allopurinol metabolite alloxanthine, which also inhibits xanthine oxidase activity (Elion, 1966) , suggest that the latter enzyme does not exert a regulatory effect on the pyrrolase activity. The selective inhibition by allopurinol of rat liver apotryptophan pyrrolase activity after administration ( Fig. 1 and Table 1 ) and in vitro (Table 3 ) and the reversal of this by excess of haematin (Fig. 2) suggest that the drug acts by interfering with the conjugation of the apoenzyme with its haem activator. In this respect, allopurinol resembles the alkaloid yohimbine (Sourkes et al., 1969) but differs from 2,2-bipyridyl or salicylate (Badawy & Smith, 1971) which only inhibit the holoenzyme activity. That allopurinol is a specific apoenzyme inhibitor is also indicated by the finding that pretreatment of the rats with it lowers the cortisol-or cyclic AMP-induced rise in the total pyrrolase activity to the corresponding holoenzyme values without affecting these values ( Table 2 ), and that added in vitro it also decreases the total activity of the enzyme induced by cortisol, cyclic AMP, tryptophan, salicylate or ethanol ( Table 4 ) to values that are either similar to, or slightly lower than, those of the corresponding holoenzyme.
The inhibition of the pyrrolase activity of cortisoltreated rats by allopurinol pretreatment (Table 2) is not due to decreased apoenzyme synthesis, since excess of haematin is effective in restoring the total activity (Fig. 2) . Activation ofpre-existing apoenzyme by tryptophan (Schimke, 1969) , salicylate which acts by displacing protein-bound tryptophan (Badawy & Smith, 1972) , and ethanol (Badawy & Evans, 1973a) is completely prevented by pretreatment of the rats with allopurinol (Table 2) , presumably because the apoenzyme there is already inactive (Fig. 1) . Inhibition ofthe apoenzyme activity in livers ofrats chronically treated with ethanol also blocks the activation of the pyrrolase by tryptophan, salicylate or ethanol (Badawy & Evans, 1973b) .
It has been reported (Curzon, 1971 ) that allopurinol does not prevent the cortisol-induced rise in "'CO2 expired by rats given a tracer dose of DL-2[-"'C]-tryptophan. This finding may be due to endogenous haem stores counteracting the inhibition in vivo. The complete prevention of the tryptophan-induced rise in pyrrolase activity in rats pretreated with allopurinol (Table 2) is consistent with the reported impairment of the hepatic metabolism of a tryptophan load and the enhanced rise in brain tryptophan after the injection ofthe amino acid by allopurinol (Curzon, 1971) . The usefulness ofL-tryptophan in the treatment of depressive illness is believed to be due to its conversion in the brain into 5-hydroxytryptamine, the metabolism of which is impaired in such illness (Curzon, 1969; Lapin & Oxenkrug, 1969) . Although the synthesis of 5-hydroxytryptamine in the brain represents a very small fraction of the overall body metabolism of tryptophan, relatively large doses of the amino acid (5-7g daily) are therapeutically effective. This may be explained by the ability of plasma proteins to bind large amounts of the amino acid (Badawy & Smith, 1972) and that most of the plasma free tryptophan is removed by the liver via the quantitatively more important kynurenine pathway. The impairment of the hepatic metabolism of tryptophan discussed above (Curzon, 1971 ) and reported here (Table 2) suggests that the anti-depressant action of the amino acid may be enhanced by joint allopurinol administration.
